35 Burst results for "Gilead"

How Jenny Lorenzo Became the Internets Favorite Cuban Abuela

Latina to Latina

05:18 min | 2 months ago

How Jenny Lorenzo Became the Internets Favorite Cuban Abuela

"Jenny. I'm almost have to admit not accustomed to seeing you as jenny. nobody else. Is that what you look like. I want to take a listen to the first video that you ever did. Hold up today. Go to pick up one three gilead of better sex for three going on meeting me gomez day metal supplement. Okay iressa on. And off for the love of god. So here's what's interesting. It's the first video that willa was ever featured in for buzzfeed but she insisted prior channel of mine called aggressive comex and a boiler was first introduced as a superhero Because this was a channel that was predominantly white male audience. I talked about video games and comic books and movies. Sifi strictly me being nerd and then at some point i did a movie review of the film kick ass and me and my writing partner for the show was to the cuban well because he knew that i kind of already did that sort of thing and so it was the same terrible wig that you do see in that buzzfeed video i think i through like baby powder on it to make gray and she had like this painted red mask over her eyes with like a fly swatter as were weapon and then eventually it made no sense for the channel. But you can tell that. I yearned to make this sort of content. It is interesting that something that is as big as a bulla takes that many iterations to get there like. I think there's a lesson in there for any creative. That is not necessarily that. The opening gambit is where you land now never being a nerd is as much a part of your identity and culture as being cuban. It seems did you see characters on tv or in media. Who has a latino nerd you identified with not really wasn't until recently that i started seeing that representation especially in a show like no spooky because these are a bunch of latino gods that are into the macab and they're a bunch of nerds and outsiders because that's a big part of me to what most approximated your own experience i would say. A lot of that was in black television. You see urkel you see. Carlton banks a lot of these like nerdy people of color on tv. Maybe sometimes says from that seventies show me. He had like a bit of a nerdy flair to him. I feel like latinos on tina's specifically were usually depicted as like very sensual loud colorful. You know things sofia vergara in modern family that was the typical depiction of what was and. So that's why. I had a hard time in the audition room. I didn't fit any mold of what especially miami casting paint a picture for me of what auditioning in miami looked like. It was a nightmare for me. I would show up and for those who don't know me. I'm like five feet pasty skinny little shits and he but then i have this like deep voice. No one knows what to do with me. So then i shopped to these auditions and they were usually little late sorta lottery or like colgate but then i would be up against women my age but they looked like supermodels and then there was me so then i just never felt like. I was sexy in us to sell toothpaste. I remember my very very first universal casting audition. It was for the florida lottery. And i had to be like this sexy. You're even an award. These like plastic clear stripper heels. I don't know. I don't know what i was thinking but i was nineteen years old. The silver lining of this terrible experience is that emotive issue to become a creator. I was tired of this. I was so tired. And then i did a couple extra work. Gigs was extra on. Burn notice and dexter. And guess what. I was scantily clad and tacky his hell because that's what they thought of people in miami. All of these shows always depicted people from miami in the same way and it always took place in south beaten always involve drugs and sex and violence. Which is another reason why. I'm working so hard today. To eventually sollers show. That depicts miami in a more authentic way so yeah it pushed me to go to school and learn how to do everything else on my own.

Sifi Jenny Willa Gomez Miami Sofia Vergara Carlton Tina Florida Dexter
ASH 2020 Update

Breaking Biotech

05:21 min | 4 months ago

ASH 2020 Update

"So. I'm excited we back and we have a lot to get into and the reason for this is that we heard a number of from the american society for hematology conference. That just took place a couple of weeks ago. So we're going to talk about updates from trillium therapeutics tgi therapeutics actinium. Pharma and i wanna do a little bit of a follow on to my video about anna back with regards to their parkinson's disease data so we're going to touch on all of this stuff and Overall is a pretty interesting conference from some of the data. Updates that i saw of course i'm just going to focus on the companies that i'm interested in but then i'm gonna follow it up with a few other updates that we saw that led to huge increases in in their stock price. So have a lot to get into. So i'm just going to get right into it. And i think before we talk about the company's specifically i did just wanna talk a little bit about non-hodgkin's lymphoma and the reason for this is that to companies trillium in focus a lot on this disease and i just want everybody to be up to speed. So i've talked about non-hodgkin's lymphoma in the past. And i showed like a version of this slide. But i've included a few like prices of previously approved drugs for these diseases just so that we all have a bit more context on what we can expect in terms of a proper valuation for the companies. So just we all understand. Non-hodgkin's lymphoma characterizes a group of malignant lymphocytes cancers. These are known as he malignancies and lymphocytes as we know at their b or t cells and these are part of the adaptive immune system. They collect mutations such that they can grow and then deposit in different areas of your body leading to non lymphoma so they're characterized based on where the lymphocytes and of depositing also whether or not they're indolent or aggressive so the inland version are very slow growing. And they're not always emergency such that they don't need to be treated necessarily immediately but they need to be monitored so the decision to treat with any of the different treatments that event lined here is really up to the doctor themself. Now when it comes to aggressive versions of non hodgkin's lymphoma there's obviously more of a drive to treat and to get rid of this cancer because it's leading to significant side effects on the patient so just to give a little bit more context here the prevalence of non hodgkin's lymphoma and this is the all of them. So i'm just including all of them in this calculation it's around twenty cases per one hundred thousand adults and this is around seventy seven thousand patients in the usa per year so it's a significant patient population treatments out there. That exist are pretty numerous. Though so there's chemotherapies immune therapies targeted therapies. And then i also put radiation stem cell transplants. And then just to give a little bit of a description on the different one. So for indolent non hodgkin's lymphoma. Cdl small lymphocytic leukemia lymphoma marginal zone. Lymphoma cutaneous t. cell lymphoma so that would be on the skin now. All of these cancers have been aggressive version. So if the indolent version gets more aggressive it would turn into these types of cancers that include p tcl deal mantle cell lymphoma or burkitt lymphoma. So keep all that in mind. And i did just wanna put here. So i'm showing a chart from various corporate presentation on Talk about them but just to sort of frame What we can expect in terms of objective response rate of what we want some of the approved drugs already. They hit ours in the range of twenty to thirty percent and then the drugs that verizon was looking at they did a little bit better. But when we're looking at whether or not therapy is is good or bad. You need a reference to compare it to so depending on where they are in terms of the line of treatment. They're looking at and the mechanism of action in the side effects. If they can garner in objective response rate of twenty thirty percent in general that is seen as decent or approvable at least for the fda now it comes to price this is also pretty critical because when we're looking at understanding the total value or potential value of a company. We really have to look at the potential addressable market so drugs that have originally like longtime ago been approved for different types of non hodgkin's lymphoma reduction was one of the original ones and right now it's approved for first line non-hodgkin's lymphoma and i didn't get into the details because they do specific indications but generally a course of this treatment for four months costs around thirty nine thousand dollars so that's kind of the the floor and then there's another one here that's approved for second line or greater see. Tcl cost around twenty nine thousand per month in this zelina but then this can go all the way up to. Yes carta which is approved for third-liner deal as a gilead drug and the cost for that is three hundred seventy three thousand dollars per treatment course so there's a big range and the total addressable market for the entirety of non hodgkin's lymphoma is around three point two billion dollars. So you have to think of all of the approved therapies that are out there and if companies are going to try and get drugs on the market you know how much of that three point two billion are. They going to be able to get for their specific drug.

Hodgkin's Lymphoma American Society For Hematolog Trillium Therapeutics Parkinson's Disease Malignant Lymphocytes Cancers Lymphoma Cancers Lymphocytic Leukemia Lymphoma Pharma Cell Lymphoma Burkitt Lymphoma Anna USA Verizon FDA TCL
Gilead's revenue rises 17% driven by sales of coronavirus treatment remdesivir

Bloomberg Daybreak: Asia

00:12 sec | 6 months ago

Gilead's revenue rises 17% driven by sales of coronavirus treatment remdesivir

"Gilead Science has reported a revenue jump of 17% that was driven in large part by sales of the code. 19 treatment room disappear. Even so, Kelly had chairs right now down about

Gilead Science Kelly
Covid: US gives full approval for antiviral Remdesivir drug

Balance of Power

01:40 min | 6 months ago

Covid: US gives full approval for antiviral Remdesivir drug

"A Corona virus being a vaccine being available by year end. And yesterday, the FDA of granted its first approval for a treatment, not a vaccine, but a treatment room disappear to Gillian. Scarlett Foods here with some of the details, and, of course, from disappear is one of the treatments that President Trump was given. After he was diagnosed. We saw Gilead Sciences, the company gap higher at the open, rising as much as 4.9%. This is a drug that was originally developed to treat Ebola, and it's now become the first covert drug to get FDA formal approval before that it was available. Under emergency used authorization. So Gilly, I can now move forward with marketing the drug, The new brand name will be victory. I'm not sure why they're changing in. There must be something more to that. But given that everyone knows that, as from disappear, it's a bit of a puzzle to me. Gillian had said it would charge US hospitals about $3100 for most patients now in terms of the numbers, analysts estimate 2020 sales will be about $2.2 billion. Cos. Expected to sell 1.5 million doses this year. One blockbuster drug, of course, can make a huge difference for biotech firm and Gillian will need it because it's getting a lower return from its research and development. Then some of its peers only 40% versus a 42% at Vertex and Bio Marin. Now the FDA approved and disappear for emergency used back on May 1st. But if you look at the stock price, it actually hasn't done that. Well. It's fallen about 23%. Sadie Group says that Gilead has first mover advantage. But that only goes so far because The drug will provide a short term boost for revenue. But sales were actually taper off in the second half, when there's more competition from vaccines and anybody treatments are in development right now make so much the scarlet food for that

FDA Gillian Gilead Sciences President Trump Scarlett Foods United States Ebola Gilly Bio Marin Gilead Sadie Group
Mirati to Rival Amgen in Solid Tumors

Breaking Biotech

08:10 min | 7 months ago

Mirati to Rival Amgen in Solid Tumors

"So to start I wanNA talk about exact sciences ticker symbol e x a s, and they are now trading at around twelve billion dollar market cap, and what they announced is liquid biopsy testing data in six different cancer types showing a sensitivity of eighty six percent and a specificity of ninety five percent, and they did kind of a grab bag of cancer types. We have lung ovarian, liver pancreatic, and Alpha Jill. And so I did video on exact sciences quite a while ago I thought their evaluation was a little bit toppy back then and was waiting for dipped to buy, and that's what I did during the Cova crisis I took a small position and then I sold just recently at around ninety four and I think is trading just over one hundred dollars right now but this. Is Nice to see them kind of moving into new areas because I think one of the things that they're struggling with is leaning on their old testing kit the colours guard while all these other companies are trying to get into things like liquid biopsy, which it's going to be a real game changer in the space. Once these treatments get validated and approved by the FDA. Now. They're not alone doing this exact sciences is kind of just finally getting into this because other big players like alumina through grail they just acquired this private company called grail officially officially. We've garden health personalisation of been floating around and invitations. Well, who just acquired archer DSL there's a lot of companies in the space, but exact scientists has shown some pretty good success in their previous testing kits. So it just makes sense them to jump into this new area and be a good competitor. So I think right now probably a little bit toppy with the price around one hundred but I'm pretty pleased with the small profit. I made given the number shares that I have. So that's exact sciences. Want to move now into regeneration ticker symbol. And they're trading at a sixty billion dollar market CAP. I did a video on them also a few months ago, looking at kind of their staples in terms of the different products that they offer and I concluded that they were relatively over-valued back. Then I think now also a little bit overvalued, but it does depend on how well their product. So and the kind of revenue they can bring in obviously but the news that we heard is that they released data on their antibody cocktail for covid nineteen. and. What we saw is that it reduced viral loads and symptoms versus placebo in non. Patients who are infected with SARS co to and what they shared our results from initial cohort of two hundred and seventy five patients, and they also have nine hundred or more patients enrolled. So this is kind of a preliminary analysis that they're showing US and they've called it a phase one, two, three trials. So they're doing the PK the safety along with the efficacy and other sorts of secondary outcomes all at once and when I look through their stuff, they started off by kind of categorizing patients based. On Sarah Negative or zero positive and I, think it's important that they do this because we're looking at a treatment for covid nineteen and if people are already sero-positive in their bodies, already mounted an antibody response in order to bring down viral loads. So what regeneration is trying to pose here is that the negative patients which means they have not mount that antibody response have significantly higher viral load and they make a better target for most treatments probably also their antibody cocktail that they're gonNA share data with. So. Then the data that they show here shows a range of efficacy based off of viral load. So we have tended the power of four copies, parallel all the way to tend to the seven copies personnel. So quite a big range in viral load here and I just blew this up on the screen. What we're seeing is that at the higher viral load, the treatment and there two different doses here in the green and the red line, we see that much more dramatic decrease in the amount of viral load in. These patients and it does kind of make sense because if your body's already mounted an antibody response, the window of efficacy is just going to be a bit smaller than if it's before the at which your body's manning response. So I think for these patients, it's definitely positive data. They also looked at other other metrics as well and I'm not going to get into everything but they did look at a day to alleviation of symptoms and they looked at the overall population of patients. It's the difference of nine with Placebo. To between six and eight, depending on the dose that they gave the antibody cocktail with the negative group alone, the placebo was thirteen days and then the low and high dose was six and eight respectively. So obviously a big difference when it comes to whether or not the patient is zero negative or positive. So that's probably going to inform the FDA when it comes to approving the drug or giving some kind of guidance on which patients should take the drug and who are likely to see more positive outcomes from that. So overall. I think it's good. It gets a step ahead of the Gilead data where I don't think we've even seen a placebo group yet. So it's nice to see regenerate actually do this placebo controlled trial. We can see whether or not there is efficacy and I, look forward to seeing the rest of the data I'm not if this merits taking a position regenerate here given that they're such a large company already and they have so many different assets that are I would say more likely to contribute to their bottom line. This doesn't entice me to take a position, but it's nice to see that we're getting all these therapies are starting to see vaccine data, and this just makes me feel better in general that we're going to move towards being able to treat this disease and hopefully get out from under this and then Kinda recover with the economy. With that, let's talk about the main story for today, and that is morality Therapeutics Ticker Symbol M rt ex, and they're trading at a price of one sixty, two point zero five per share giving them a market cap of seven point two, billion dollars. Their Q. Two, twenty, twenty, net loss was eighty, three, million dollars, and this represents an eighty percent increase year over year there their q two net current cash is six, hundred million dollars giving them a runway of about until twenty twenty two I would say but let's also be careful that if they see positive data. This year or next year is a good chance that they're going to raise again. And what Morad is trying to do is develop targeted cancer treatments and they're specifically looking at solid tumors and even more specific than that are K. Rasa inhibitors, and so they have to compounds Marta six, eight, four, nine, and x, one, three, three. They're also looking at checkpoint inhibitor resistance with their compound sicher Vance it, and I'll talk about that in a bit later. To start though we gotta talk about chaos and the reason why this is so important is that chaos mutations are present in a large population of cancer patients. The first thing it's important to note is that chaos is pretty ubiquitous. It's a critical part of the map kinase signaling pathway, and this is very important in basically every single cell. This pathways involved in Cell Proliferation Cell Survival had differentiation here. There's a whole bunch of other stuff and it makes a little bit confusing because it is involved in. So many different pathways that if you were just to inhibit this molecule non specifically, you're likely to see significant side effects with patients. It's for this reason that it's important that we can come up with a targeted therapy that will only target cells that have a mutation in chaos rather than the healthy normal. KS. To talk a little bit more about its function, it works as a GT as and what this means is that it takes a molecule GDP converts it to GDP using that phosphate group to continue the signaling pathway. The next step is Raff or something like that mutations in. A company twenty, one point, six percent of all human cancers, and then I have here that chaos the predominant or exclusive Rask's mutated in three of the top four neoplasms that account for cancer deaths in the US lung colon and pancreatic. Cancer.

FDA United States Cancer Alpha Jill Sarah Negative KS Raff Rask Manning Gilead Solid Tumors Morad Marta
Trump receiving remdesivir antiviral drug as part of experimental treatment

Weekend Edition Saturday

00:50 sec | 7 months ago

Trump receiving remdesivir antiviral drug as part of experimental treatment

"Trump's physicians as the president is being treated with room to severe. NPR's Joe Palka reports. That's a drug usually reserved for hospitalized Covad 19 patients who are quite ill. Rendez severe, is an antiviral drug made by Gilead Sciences. It's administered intravenously, typically to hospitalize patients for five days, 10 days for sicker patients. So far, the best medical evidence suggests the drug reduces hospital stays by about four days. It's not clear if it prevents deaths from Cove in 19. An expert panel, convened by the National Institutes of Health concluded there are insufficient data to recommend either for or against the use of ram best severe in patients with mild or moderate cove in 19. The president also received an experimental monoclonal antibody therapy made by the company. Regeneron

President Trump Joe Palka Gilead Sciences Cove National Institutes Of Health Donald Trump NPR
The Obviously-Going-To-Die Stocks

MarketFoolery

19:19 min | 7 months ago

The Obviously-Going-To-Die Stocks

"We're going to start with the stock of the day. Don't call it a comeback bed bath and beyond has been here for years. It's just all that time someone else was running the company but now that Mark Trittin has been in the Corner Office for about a year. We're seeing days like today second quarter profits came in exponentially higher than expected. Same store sales were positive for the first time in four years. The stock is up more than thirty percent this morning. I'm assuming at least part of what we're seeing with the stock is some shortsellers saying that's it. I. Think. I'm. Probably. Bed, bath, and congratulations to march written and Beth by best buy bed bath and beyond. For this quarter, March, written formerly of target, of course, and a few other places before that, I think Nordstrom's and I believe. He had a stint at Nike to could be misquoting. This bed bath and beyond is in a group of companies retailers that I like to call the obvious obviously going to die crowd. And the funny thing about companies that are obviously going to die when they get the right mix of management decision making and in some help from the environment and you know just a little bit of because no one's more aware of a company's struggles at least no one should be more aware of a company struggles then the people inside the company. And that's when you plan your strategy. What are our tools? How can we navigate our way through whatever we found ourselves in business is not easy and certainly for this group retailers that I'm Gonna I'm GONNA hold up. Bed Bath and beyond as one Chris. But you know how about Game Stop Game Stop. The seller of video game systems and Software that of course is going to be the next blockbuster. Right if they writing that headline since two thousand and nine, how `Bout Michael's the craft store everybody knows I. Y has an Amazon run over. And the granddaddy of all of these. Companies that are obviously going to fail. They're obviously going to be taken bricks and mortar is dead is best buy which just before the podcast we were talking about how? How many listeners? Realize, that best buy has been at ten bagger over the past decade they went through some struggles they brought in new management. WHO had a plan? and. I'm sure they were mocked and I'm sure people were skeptical and they executed on that plan and best buy, which was a sub twelve dollar stock in. Two Thousand Ten two thousand eleven is today roughly one hundred twenty dollars stock. And so when you see. I'm a kick myself a little bit on dust by iron best buy bed bath and beyond his too many bees. Bed Bath and beyond. I actually did a little bit of work about a year ago as I was discussing with one of our with one of our foolish coworkers. About this basket of Taylor's who are sure to die. And we had this one. We had game stop we have Michael on the docket and I went through you know what this company's history of cash flow was and what they've done with it and how they've raise capital, and this is before Mr Trenton came on but I. It laid the groundwork for someone with. A better vision to come in and knocked the ball out of the park which you've seen today and and best bed bath, and beyond is as we speak it's now a six th bagger since March of this year and so in the a roughly a year ago when I did my work because I was vigorously debating co I pointed out that in the previous six years here was bed bath and beyond had produced four point two, billion dollars in free cash flow. They had also issued one point five billion dollars in debt and debated smart about the debt because the debts. Basically staggered I think is a ten twenty and thirty years. and. They have to pay it back anytime soon, and they had gone on a massive buyback program. They've they've retired a ton of their shares. Now. Slowly melting ice cube no one's going to want to own this business what have you. But at the time the stock was about ten eleven dollars the company is training but four times enterprise value of free cash flow. that. That is rock bottom fools that is something that is going to go away. That's what the market is telling you. Flash, forward, to today and oh positive cops. Oh. We have a plant. They've they've suspended their dividend they've they've halted their. They've halted their. They suspended the dividend halted their share buyback plan I believe in. April. But with this. With this. report, they have generated a ton of cash flow. They've deployed it smartly they took down some temporary which they had out as part of the PARCO vid. They have bought back twenty percent of that long dated not in any danger to come calling debt they bought that back at a discount. Which is brilliant. They. So they're down to their down net debt down by about thirty percent from where they started the year. They have a store optimization program, which is something that a lot of these retailers the slowly melting ice cube crowd will call them. They are reducing their store count 'cause they don't need it because they can move to ECOMMERCE, which they've done a little bit they can move to. The geography is able he served by less stores and you see a lot of. Traffic that previously went through one store transitions to another and. They are steal a Ron grosses them here they are firing on all cylinders and I'm not sure. Anyone. Thought is coming. I am I am both thrilled that they are doing this they're having success because everyone loves a comeback. I'm less thrilled that you own it and I don't. But. That's mainly because I had this in my hand a year ago Chris and I'm holding it up. The skull of York. And and I'm looking at it and I didn't at least put a little field position because as I said, at the time training for four times free cash flow that is close to no-brainer territory for me. So two other quick data points before we go to our next story. Not. Surprisingly digital sales of big driver this quarter. That goes hand in hand with the store closures so Another smart move by Trittin and his team. And also Happy to see that they're you know suspending the dividend that they're. Suspending the sticking with the we're not going to buy back shares. I'm also happy to see they're not offering guidance. Their New Orleans. No need to at this point. Let's move on the third quarter sales, for Pepsi, grew five percent and. Kind of like we saw three months ago snacks and some of the beverages particularly the Seltzer. Part of their portfolio helping to make up for the fact that somebody restaurants are closed. So many sports and entertainment venues are closed and. That's that's the stock is basically flat and this kind of flat for all of twenty twenty but. Nice to see that the the salty snack part of the business is making up for the sort of the tried and true Pepsi part of the business. Gilead household particularly the soon to be sixteen year. Old Member of the Gillies household has been doing his part to. To to help with the salty snacks portion and shareholders. Thank him. Yeah I was GONNA? Say. You know dude. There are other food groups other than Doritos. Look it was a perfectly acceptable boring quarter from a perfectly acceptable boring company and and I think you know Chris but maybe some of the listeners not know. For, me to call a company perfectly boring from for me. That's a compliment because I like businesses that are boring. Not Terribly exciting person myself I enjoy. Investments in companies that just actually do what we expect them to do, and essentially just get it done quarter after quarter. Pepsi is not GonNa. You know if you'RE LOOKING FOR PEPSI TO BE A. Ten bagger. You know anytime soon like the aforementioned by we mentioned earlier. That's not gonNA happen. They are just a steady bedrock performer for your portfolio and we all need a few of those. So we can go after the more exciting things in our portfolio. Yes. So it was it was A. It was a boring it was a boring quarter but boring is nice because boring boring says, oh, we end up four four plus percent on. Organic revenue growth total revenue growth went up five plus percent. EPS Is up ten percent year-over-year just for the quarter. It's still down for year to date, but of course, Mindy Stan why because the previous quarter? Cova. no-one no-one was new what was going on? So we kind forgive that. They are they're pointing towards the full year. They did give guidance their point point to a full year of approximately four percent revenue growth approximately five fifty core earnings. Stocks at about one hundred, forty bucks. So it's not cheap. But it's not terribly expensive, and again, this is one of those widows and orphans stocks. You can buy put it away and we'll see you when you retire. Hugh Johnston, who's the CFO at Pepsi? Granular on CNBC this morning talking about because when you think about all of the food and beverages they have across their portfolio he got granular talking about the new cheetos macaroni and cheese saying you know they're trying to keep up with demand as a fan of both cheetahs and macaroni and cheese I haven't tried it yet but I can see why it's popular. Any. Do they give any color on the? Two. Portals that they were direct to consumer sites that they launched earlier this year snacks dot com and Pantry shop dot com. Sadly, Chris they did not at least in the conference call or the press the presser maybe in the ten Q I haven't read the ten q yet obviously but. Yeah no snacks dot com I can confirm both of those sites are open and accepting offers as of this moment. SNACKS DOT COM and Pantry shop I think is an interesting one because they are. You know you are buying your you're you're buying all of your Pepsi Slash quaker products. Simultaneously in in in the various groups. So if you want your everyday Pantry, you want to get your your oatmeal and your healthy. Your healthy Chia bars and your rice cakes do people still eat rice cakes and if so why? You can get all those delivered at the same time or your snack package your breakfast package You know it's it's interesting to to have it delivered. I I'M NOT A. I I'm one of the three people in North America is still doing own grocery shopping. So I'm probably target here but I know a lot about the people how to use it and I think probably if I let my as I mentioned a sixteen year old note that this thing existed. It might be his only source of nourishment. So yeah, don't don't. On, the first time I went to that website I kind of went crazy to the point where in the box showed up to two days later even my kids were just like. This is a lot of snacks and was like, yeah I may have ordered too many but but I regret nothing. Playboy. Enterprises is returning to the public markets after nearly a decade and because I was are out of fashion, playboy is going to be doing this through a speck. Mountain Crest acquisition is a current special purpose acquisition company that is going to be taking playboy public through a reverse merger and wants to deal is done that company where the ticker is MC. ABC? Is. The playboy name and the ticker symbol P L B Y? I guess I, I saw this story and I thought, okay I'd that's one way for playboy, which is a private company and has been since twenty eleven. I. Guess That's one way to raise money. I, I, I'm hard pressed though to think that. The second round of playboy being a public company is going to go any better for the company and for investors than it did the first time around. That was my initial take as well, and you say it's one way to raise money I'd say it's one way for insiders to cash out. Tomato Tomato. The more I think about this though. I could be spectacularly wrong and it wouldn't be the first time. This might be quite this might be interesting I can see. I can see a number of thing, and I just find this interesting from a number of re. I as you point out. Yes, playboy. Is private the SPEC the Special Purpose Acquisition Company Mountain Crest Acquisition, company. It's out there. Now it's got. It's a walking wallet got a bunch of cash their stocks over ten dollars specs go at ten bucks. There's nothing you can. You can go buy today Chris if you want. And You can just sit there and wait until the transaction is completed in q one. If. You WANNA own playboy. So, playboy today is not playboy of the past for thing, magazines have died. So, there are no issues of the iconic famous magazine. These no regularly published issues and I believe they went to quarterly publishing versus. Monthly publishing before that. So what playboy is trying to be or this new iteration trying to be a licensing company and they're calling it across four major categories they're saying sexual wellness, which I'm just going to skip to the next one, which is style and apparel which is. Apparel. and accessories for men and women globally gaming and lifestyle also digital gaming hospitality and spirits. So you can get yourself some playboy-branded Bourbon. And beauty and grooming, which is fragrance skin care grooming cosmetics for men and women. Okay. That sounds interesting. They're not a publishing company more avoiding that and I guess they have a bunch of online stuff as well which. Tell people they can go look on their spare time but. They are calling themselves a streamlined high growth business. The company has four hundred million in cash flow contract through the next eighteen years. and has products available for sale and in ten thousand major retail stores. In the US, this is a brandon company. Now, now, what you think of the brand and what you associate with the brand, the iconic a bunny ears brand, of course. Is Is. is going to be probably a nuanced and varied. I can understand why some people. Would not want to do with this brand I completely understand that is not. Bend the most shall we say progressive brand in history? It has fostered some. Attitudes, particularly women that. I think it's fair to say some would find distasteful and I I completely understand why? And for those people, they're just not going to be shareholders and that's that's fine. But what I find interesting about this if this, if the licensing deal and we have, we've already had a certain dry run of this in. Do you know the magazine Maxim? It was. So it's a men's lifestyle magazine, girly pictures, and whatever it was bought by an entity called big holdings. I'm going to say eight nine years ago. With the goal of they went into change it from the the lad magazine into more of a lifestyle brand licensing deal what playboys doing. Now. I mentioned earlier it's important to have You know leaders businesses, you respect and trust big lorry holdings is not one of those businesses but I do know that they even though they're circulation sales are down significantly there they have turned that profitable on a small scale with the licensing strategy. I suspect the playboy will do a better job. And It will depend on the valuation coming out but you know when analogy I might throw up as. As a comparison is. Franchising businesses in the in the restaurant space. So a restaurant brands international, which owns importance and Burger King. Dunkin brands, which of course owns your beloved Dunkin donuts. Those are those are check cashing businesses, they they sell the franchise to a Franchisee. And then take tax six percent of their gross sales and royalties every month plus x percent for advertising they sell you a system and so those are very asset light cash-rich capital Genita- businesses. And part of me wonders here it's obviously not the same as selling. Coffee and whatever. But part of me wonders if that is what this business will look like, and if they are truly in the growth business and the cash generation business, this might be an interesting opportunity. And you just hit on what I think is the most interesting thing to watch. Once it becomes a public entity again, the high growth aspect of this because now we're going to see Now, we're GONNA see through quarterly reports. Okay. Are you growing? Because that's one of those things where we investors and the market in general get to decide what we consider to be high growth And I again I had I had your initial take which was. Oh please. Like if it didn't work the first time. It's going to work less well this time. The more I read about like. I'M GONNA keep an eye on this. Curiosity. Jim Gillies always talking to you. Thanks for being here.

Playboy Chris Pepsi Mark Trittin Jim Gillies Michael Mountain Crest Acquisition Nordstrom Nike Beth Corner Office North America Amazon United States Taylor Hugh Johnston Cnbc
Merck to Invest $1 Billion in Seattle Genetics

Bloomberg Surveillance

00:54 sec | 7 months ago

Merck to Invest $1 Billion in Seattle Genetics

"Which is more than doubled up 106%. This company makes the cancer drug traditional V had accepted a $21 billion takeover offer from Gilead Sciences now tried. L ve won. US clears in April to treat triple negative breast cancer and immuno medics plans to seek broader approval later this year. You've also got Merc moving into breast cancer treatments as well. A Seattle genetics up 9% after Merck agreed to invest a billion dollars in the drugmaker. At $200 a share as 33% higher than last week's close. The purchase is part of a Siri's of deals worth as much as $4.5 billion for two breast cancer drives, and indeed one of them Treats triple negative breast cancer, so you'll have a competition to Gillian A. Merc in that segment of the drug industry varieties is up.

Gillian A. Merc United States Gilead Sciences Siri Merck Seattle
Evofem To Launch On-Demand Contraceptive

Breaking Biotech

05:16 min | 8 months ago

Evofem To Launch On-Demand Contraceptive

"Today we're GonNa talk about a company that is trying to commercialize a female contraceptive and the company's called Yvo FEM and their product is called sexy and it's going to be launched actually in the next few days. So I wanNA talk about them as the main story, and then we're going to start with some updates from Gilead O'Donnell as well as bio Merrin and actually we got some news from Amarin today that I'm GonNa touch on just very very briefly because I haven't. Totally incorporated it into my portfolio yet, but we did see some dramatic news from them. So with that, let's get going and the first thing I want to talk about is the Gilead, news that we heard and what we found out is that they were issued a complete response letter for the approval of Phil God's Nib, which was their treatment for rheumatoid arthritis. So, this is a bit of a surprise I would say and Phil God was going to be something that replaces revenue streams that are slowly starting to fall off a patent for Gilliat and they're gonNA start to feel that in the form of loss of revenue and forgotten it was kind of shoe into get approved by the FDA issued them this complete response letter saying that they will not approve the drug unless certain conditions are met and usually when companies receive Sierra L. either it's unconditional in the sense that they don't have any recourse or it has conditions on it and hear what we. Found out that the FDA wanted more data from their face, three Manta and Manta Ray studies before completing its reviewed, the NBA and they're specifically concerned about issues in male sex organs. So Gilead is going to have to provide this data, the FDA before they will approve it, and it looks like from what I looked very briefly on the clinical trials dot Gov site is that the primary completion date isn't until early twenty, twenty one where they final completion date of twenty, twenty four. Now Juliette is pre savvy. So I feel like they'll be able to eventually overcome these hurdles once they provide some data. So I. don't see it being long long-term hindrance of the company, but we've seen the stock get hammered pretty hard since the glory days of remedy severe and in general has been kind of slow to adopt new therapies to their pipeline in order to maintain that growth that people expect. So hopefully, with the approval of Fil gone, they'll be able to replace those drugs that are falling off of patent and be able to maintain their value that way. But personally no position for me from Gilead but I thought it was interesting to point this APP. Nasr Company. I WanNa talk about is by Merrin, and they are trading at a fourteen billion dollar market cap now, and they were also issued a complete response letter for Rock Avian and this was their hemophilia, a gene therapy and I've touched on Hemophilia A and. A number of different videos but I haven't touched the topic in a while. I did notice the CRO though and it's interesting because the conditions that the FDA wanted in order to approve the drug was evidence from two years of data for its ongoing phase three trial to support the durability of the gene therapy. So this is obviously kind of rough for the company because the bar is rarely set this high for other companies that two year window of therapy is going to be maintained. This has me questioning the gene therapy space as a whole that you know other companies that have invested in say route Jenex bio if they're going to have to show two years of data to show that it is a Gerbil effect, this obviously plays into the models and delays the time at which it's GonNa take for them to get revenue. So kind of. makes. Me Nervous about the gene therapy space but you know different diseases seem to have different thresholds for what the FDA wants and it's tough to predict. So thought it was worth bringing up and just for those who are actually following by man, their last phase three patient will complete two years of follow up in November twenty, twenty, one, serve you're expecting revenue from this drug. Now you're GonNa have to wait until twenty, twenty two proudly see any revenue. So that's a disappointment even though the drug does help us significant number of patients. All right. Moving on I WANNA touch on otani therapeutics ticker symbol od T, and they're trading now at around five hundred, seventy, four, million dollar market cap for those that don't remember I, touched on this a while ago they were short candidate that I had once I seemed like they had a run up in the stock for no obvious reason, and then I sold it off in anticipation of run up to this event that we just saw news to, and they're commercializing a tax seen that is given orally. So right now has to be given IV in a lot of complications surrounding that a lot of hurdles that patients he'd go through to get this. Treatment and it's Kinda tedious. So if he can come up with an oral version, it would be much better for patients and that's what Oh Donald Trump do here. So what we heard is that their face three contessa trial achieved primary endpoint and what they were looking at is test attacks will their drug plus bean compared to just capital being alone, and the results showed that the progression free survival was significantly better in the tax will plus Kapustin group rather than just cap aside to being alone nine point eight months versus six point nine months with a hazard ratio of zero point seven to just pretty good and value point zero, zero three.

FDA Nasr Company Phil God Gilead O'donnell Merrin Donald Trump Amarin Manta Ray NBA Juliette FIL Kapustin Group Gilliat
Dow Jumps As Gilead Says Remdesivir Coronavirus Treatment Reduces Risk Of Death

Bloomberg Businessweek

00:30 sec | 10 months ago

Dow Jumps As Gilead Says Remdesivir Coronavirus Treatment Reduces Risk Of Death

"That laid Corona virus fears in the stock averages gained 2/3 to nearly 1.5%. The Dow rose 369 the NASDAQ 70 to another record close at 10,006 17. Yes and Pete gaining 33. Those gains followed an analysis of Gilead sciences drug round death severe, which indicates it may have reduced deaths of Corona virus patients by 62%. Dude sent Gillian shares 2% higher and allowed investors to ignore another record increase in cases of the disease. Facebook has been

Gilead Sciences Facebook Gillian Pete
BioNTech aims to seek approval for Covid-19 vaccine by year End

Curtis Sliwa

00:16 sec | 10 months ago

BioNTech aims to seek approval for Covid-19 vaccine by year End

"Biotech partner Beyond Tech said it'll be ready to seek approval for its Corona virus vaccine by the end of the year. The company tells The Wall Street Journal. Several 100 million doses could be produced even before it's approved. Another drug company, Gilead says tests

Beyond Tech The Wall Street Journal Gilead Partner
"gilead" Discussed on Daily Coronavirus Update

Daily Coronavirus Update

06:28 min | 10 months ago

"gilead" Discussed on Daily Coronavirus Update

"People on private insurance, it will cost three, thousand, one hundred twenty dollars or a five day treatment. Gilead says that he could save hospitals about twelve thousand dollars per patient. Zachary Brennan reporter at Politico joins us for more on the cost of treating cove in nineteen. Thanks for joining Zachary thanks for having me. Talking about cove in nineteen, and the costs associated with it right now, the drug maker Gilead has now set a price for their drug rim desert. On how much it's GONNA cost for the United States is a little weird. There's two different prices whether it's for the government price, and then perfect people on private insurance. Zachary tell us about what this is going to cost. People sure so yeah Gilead. Put out a press release early this morning. basically explaining how for those on certain government programs through. Through the United States, federal government that'd be paying two, thousand, three, hundred and forty dollars for a five day, course of treatment or three hundred ninety dollars per vial and then if you're using private insurance in the US, you'd pay three, thousand, one hundred and twenty dollars for five day course of treatment, or about five hundred twenty dollars per vial. Why is the United? States getting this these two different prices? So according to Gilead the price. Difference is because they basically claiming it's the way that the US system is set up and the the way that hhs explained it on the media. Call this morning was the va was able to negotiate the price down considerably or thirty three percent from the the price. That'll be for you know. People covered under private insurance. And the interesting thing that is associated with this and I, think they. They brought it up in the in the house. Before is that the United States has a stake in this already through the National Institutes of health. We've run clinical trials on this. We've helped pay for some of the development on this, so that's kind of another wrinkle in this you know with why we're getting two different. Different prices yeah exactly so Naiad which is a division of the National Institutes of health ran the major study basically establish the efficacy of does Aveer, so there have been several lawmakers several democratic. Lawmakers who are basically calling this price outrageous in saying you know it needs to be subsidized further because of the amount of taxpayer funding that went into You know the development of this drug. For Gilead for their part, they say that on average this could reduce hospital caused by twelve thousand dollars a patient and this is because in the study Rendez Desert. Your was said to reduce a hospital stay for a person by about four days, and I guess they averaged about three thousand dollars a day for a hospital visit, so they're saying that it saving everybody twelve thousand bucks. Yeah exactly and secretaries are really Kinda playing that twelve thousand number and some of the other biotech analysts, or basically saying you know Gilead invested over a billion dollars in the development and manufacturing of this drug and you know again do. Gilead also donated one point? Five million doses of the drug prior to setting this price so You know there's a there's a strong push from investors to kind of recoup more of what Gillian has put in so up until now. That was one of my questions. WHO's paying for right now up until now? This has all been donated by them. Correct yeah. So! How's this whole thing going to work? The health department and the states are going to be managing how this is all allocated. So as they did, with the previous donated doses HHS is working with killiadts. Trish distributor a source Bergen and basically deciding what states should be allocated. What number of doses based on an algorithm on you know how? Many coronavirus cases or taking place each week and each month, and then they're shipping the doses to the states via marriage source Bergen, and then the states are basically deciding how to divvy up the doses per hospital. And, so what's next for all of this? Now that this price is set, a lot of people were saying that this kind of since there's this is one of the first drugs that's shown to prove effective against nineteen. They're kind of setting the bar or other drugs. We had already heard about that. Other steroid. decks method zone that could possibly help in the treatment of cove in nineteen that's a widely available drug already, but with this one coming out with the pricing structure on this They're kind of setting a bar. Yeah they they definitely are sitting a Bar I guess the main difference between this and methods techs zone as a cheap generic, so another generic firms are going to be setting prices for this, but there are other. You know possibly better molecules that are coming out. That are in development in clinical trials right now there's a certain class of drugs called antibodies that could prove to be very effective and could also be priced. You know quite high but again I think Gilead really sets the bar here with deciding on this price, and it's very unique especially in the FA Gilead hasn't even wonderful. FDA approval for does of Area Right? They're still working under this emergency. Use Authorization. Zachary Brennan reporter at Politico thank you very much for joining us. I'm Oscar Ramirez and this is reopening America. Don't forget that for today's big news stories. You can check me out in the daily dive podcast every Monday through Friday. So, follow us on Iheartradio or wherever you get your podcast. I'm Alex Iona and I have a new podcast. Let's get into. It is all about tackling the stop you and I. WanNa Know Each week I'm joined by a friend and a wisdom tree, and we discuss everything you want to know about money. Sacks love your relationships, even fitness and mental health. I love having deep conversations with my friends, and now it's your turn to get. Listened to Alex Iona. Let's get into it on the iheartradio. APP, apple podcasts or wherever you get your podcast launching July seven..

United States Zachary Brennan Gilead Politico hhs reporter National Institutes of health Alex Iona Bergen Rendez Desert Iheartradio Oscar Ramirez FDA Naiad Gillian apple Aveer
Gilead's remdesivir will cost $3,120 for private insurance

AP 24 Hour News

00:44 sec | 10 months ago

Gilead's remdesivir will cost $3,120 for private insurance

"Has helped reduce the effects of Copan, 19 and some patients will cost thousands from desert here has been shown to shore in the recovery time for seriously ill Cove it 19 patients maker Gilead Sciences says a typical treatment course will cost people under government health programs and the U. S and other rich nations. About $2300. It will be roughly 3100 for those with private insurance in setting the price. Gilead CEO says it had to focus on wide access to the drug and not solely on value to patients. But the cost is being criticized by a consumer group who calls it an outrage and buy a Cleveland clinic doctor who says he'd prefer the government take over production and distributed for free.

Gilead Sciences Copan CEO Cleveland U. S
Gilead's coronavirus treatment remdesivir will cost $3,120 for patients with private insurance

Morning News with Manda Factor and Gregg Hersholt

00:24 sec | 10 months ago

Gilead's coronavirus treatment remdesivir will cost $3,120 for patients with private insurance

"A drug that has been shown to shorten recovery time for severely ill covert patients. Says it's quite a charge $2340 for a typical treatment course for people covered by government health programs in this country. Gilead Sciences announcing the price today for rendez severe. And says the price would be $3120 for patients with private insurance. The

Gilead Sciences
"gilead" Discussed on AP News

AP News

13:11 min | 10 months ago

"gilead" Discussed on AP News

"The first drug proven to show a benefit in the corona virus pandemic now has a price tag when disappear has been shown to shorten the recovery time for seriously ill Colby dying teen patients maker Gilead sciences says a typical treatment course will cost people under government health programs in the U. S. and other rich nations about $2300 it'll be roughly 3100 for those with private insurance in setting the price Gilead CEO says it had to focus on a wide access to the drug and not solely on the value to patients but the cost is being criticized by a consumer group who calls it an outrage and by a Cleveland Clinic doctor who says he preferred the government take over production and distributed for free Sager made Ghani Washington

Colby Gilead sciences Gilead CEO Sager Ghani Washington Cleveland Clinic $2300
Gilead prices coronavirus drug at $2,340 for rich countries

AP News Radio

00:47 sec | 10 months ago

Gilead prices coronavirus drug at $2,340 for rich countries

"The first drug proven to show a benefit in the corona virus pandemic now has a price tag when disappear has been shown to shorten the recovery time for seriously ill Colby dying teen patients maker Gilead sciences says a typical treatment course will cost people under government health programs in the U. S. and other rich nations about twenty three hundred dollars it'll be roughly thirty one hundred for those with private insurance in setting the price Gilead CEO says it had to focus on a wide access to the drug and not solely on the value to patients but the cost is being criticized by a consumer group who calls it an outrage and by a Cleveland Clinic doctor who says he preferred the government take over production and distributed for free Sager made Ghani Washington

Colby Gilead Sciences Gilead Ceo Sager Ghani Washington Cleveland Clinic
Gilead prices coronavirus drug at $2,340 for rich countries

AP News Radio

00:47 sec | 10 months ago

Gilead prices coronavirus drug at $2,340 for rich countries

"The first drug proven to show a benefit in the corona virus pandemic now has a price tag when disappear has been shown to shorten the recovery time for seriously ill Colby dying teen patients maker Gilead sciences says a typical treatment course will cost people under government health programs in the U. S. and other rich nations about twenty three hundred dollars it'll be roughly thirty one hundred for those with private insurance in setting the price Gilead CEO says it had to focus on a wide access to the drug and not solely on the value to patients but the cost is being criticized by a consumer group who calls it an outrage and by a Cleveland Clinic doctor who says he preferred the government take over production and distributed for free Sager made Ghani Washington

Colby Gilead Sciences Gilead Ceo Sager Ghani Washington Cleveland Clinic
Gilead's $2,340 price for coronavirus drug draws criticism

Charlie Parker

00:13 sec | 10 months ago

Gilead's $2,340 price for coronavirus drug draws criticism

"Room does severe will cost a substantial amount of money the drug's been approved by the FDA for use in treating some coronavirus cases it's maker Gilead sciences says the cost of a five day course of treatment will come to nearly twenty three hundred fifty

FDA Gilead Sciences
Testing if an Approved Antiviral May Prevent COVID-19 Outbreaks

The Bio Report

03:57 min | 11 months ago

Testing if an Approved Antiviral May Prevent COVID-19 Outbreaks

"For pilly therapeutics to begin a face to study of an approved antiviral therapy as a potential preventative treatment against covid nineteen outbreaks, the study will enroll seven hundred sixty participants who are in long term care facilities in Ontario. The others are looking at the drug as a possible treatment for covid nineteen. This is the first study to consider its potential to prevent outbreaks. We spoke to Armand. Balboni see Ova pilly about the drug how it works and its potential to prevent outbreaks of covid nineteen in high risk populations. Armin thanks for joining us. Great to great lengths. We're going to talk about a guy. Its efforts to repurpose an approved antiviral as a prophylactic treatment against the covid nineteen virus in patients, long term care facilities in Canada for people, not familiar with the company. What does APU I do? Pillai Therapeutics was started. Twenty fifteen as an as a company in the anti infective space to address unmet needs. In. Fairly creative way we, we really are in global fighting instant action broadly, and what that means is, we are agnostic to a particular technology. We don't suffer from wasn't invented here, so we don't like it. We really look for the toughest problems in infectious disease, and then go and try and find solutions that could be an antibacterial, antiviral, anti, fungal, or accedes, which we actually have all of those so that that really is a little bit of different approach many. and. You're sponsoring the first clinical trial evaluating VIP Aveer for the prevention of covid nineteen. What is? there. So. The drug is a broad spectrum antiviral, and what that means is it has activity active against a wide range of viruses in this case there any viruses, so things like influenza. Ebola or I I had a chance to look at this in a couple of other agents. LHASA FEVER A Disease that endemic in. An Africa and of course songs cokie to. OR OF A. Ninety, and so it is a broad spectrum antiviral. Proof for influenza Japan and we noted that because of that activity. It is probably a great drug with a lot of safety data to to try against Cova Antena and that's binding. You actually had experience with the drug back when you were a staff officer at the US. Army Research Institute of Infectious Disease. What was your experience with the drug then? I was I. was at you Sam read actually. I was on I'm an officer been an officer? The US Army as both MD end of. Upper over seventeen years, and so what that means I've worked on a number of anti effective programs. The US. Department of Defense sent me to to the food and Drug Administration at two thousand fourteen for the outbreak, and it was during that whole. Albert but I had the opportunity to work as part of the review team reviewer in. In the FDA and looked at both from severe trump. It's now being used by Gilead and Santa Peer Review I'm so both drugs are broad spectrum. Antivirals and had had an opportunity to look at how they were against a some Arnie viruses legal.

Officer United States Army Research Institute Of Inf Us Army Pillai Therapeutics FDA Department Of Defense Cova Antena Armand Ontario SAM Lhasa Santa Peer Review Armin Vip Aveer Africa Japan Ebola Fever Albert
"gilead" Discussed on P&L With Pimm Fox and Lisa Abramowicz

P&L With Pimm Fox and Lisa Abramowicz

05:40 min | 11 months ago

"gilead" Discussed on P&L With Pimm Fox and Lisa Abramowicz

"Because that's the way back in March I. was just you know? Nobody had any appetite for anything emerging market? Yeah, exactly. This is Bloomberg markets with Paul, Sweeney and Bunny Quinn on Bloomberg radio. Markets the man said so. Let's get to our next conversation now. With virologists from Harvard University Dr Peter Kinski actually extremely excited to speak with you. The author of the Great American drug deal new prescription for innovative and affordable medicines so Dr Kaczynski. Will it be the great American drug that provides us with our vaccinations, or will it be great Chinese drug? Thank you very much for having me on the show I should point out. I. I am a scientist by training. I did my of Raji training at Harvard but for my whole career than a by technology investors venture capitalist, so I. Look at this industry from the standpoint of an investor, evaluating a lot of different companies and I think that while China has been a larger player in drug development industry over the last ten fifteen years. I think that? The Kobe response globally has been someone nationalistic, and my guess is that China's going to conserve its vaccine doses for its own people and you know Europe is looking to lockdown doses, and so the US is going to be getting those from companies that its contract with. So Peter! You know some people talking about you know whoever gets at first, maybe just license it to everybody else for the common good. Is that a is that something you think could happen here, or is this something that maybe some of these companies are going to look to profit off of? You know if only at work that way, but you know the. Getting there I it's not like writing a book and being able to just hit publish, and then there's infinite downloads you know you can get there first, and then you have to actually scale up manufacturing, and so the first vaccines that are likely to prove out maybe later this fall They're still going to be constrained by the fact that you know companies. Companies are going to be scaling up manufacturing, and maybe getting to the point of tens of millions of doses if we get to a hundred million doses by the end of this year, collectively across a few vaccines that'll be amazing, but that's not enough to vaccinate you know even the the US let alone US Europe and all the other countries that are out there..

Dr Peter Kinski Bloomberg US Dr Kaczynski Harvard China Europe scientist Raji Bunny Quinn Kobe Paul Sweeney
"gilead" Discussed on P&L With Pimm Fox and Lisa Abramowicz

P&L With Pimm Fox and Lisa Abramowicz

03:34 min | 11 months ago

"gilead" Discussed on P&L With Pimm Fox and Lisa Abramowicz

"All. So I, it's one thing to have the idea of the price, but you absolutely nailed down deal and. Virtually shake. House on it. is difficult now. This is what happens if the pandemic hopefully eases and conditions for watching having face to face tools. doing more substantial children's become much easier then then than. That point! Does this become much more? Will we will continue to watch the space with acute interest in our thanks to both of you. That is Chris. And Max Nielsen both. Internally here on Bloomberg, reporting on. Pharma and of course has been a phenomenal job throughout the pandemic as well just on the veracity and everything else Paul. How was your first day on Bloomberg markets Oh my gosh. I felt like A. Bicycle in the first place. Great to have you on board. We'll do join US tomorrow. Another full slate on looking forward to being back in the chair from pulse, lenient missile. Vonnie Quinn and everybody else here. This is Bloomberg. Delighted, bringing in our next guest now, a regular on the show bill, SNEAD joins us from Seattle bill great to have to discuss these markets. Robina so when the market lows back in March your son Cole was on. They said it was one of the great stock buying opportunities in history. It's clear that he wasn't wrong. When you have the likes of Stanley, dock and Miller, he didn't take enough risks at the lowes. What did you do exactly? And how is the trade workout? Well we tack toward the opportunities that were created by the complete destruction of economic optimism. And we operated under the theory that at major historical change points. The existing trend gets exacerbated the positive part of it to the upside, and the existing trend gets exacerbated to the downside, so what you had was a complete and total capitulation on value and it complete you've you've had the biggest growth or maybe ever. In the last. Four or five years, so that was exacerbated. In March we could see that, even though we were practically nauseous every time we put in by order, we tacked toward the deepest most out of things that people thought wouldn't come back anytime soon. They thought it was going to be years before anybody wanted to go shopping. And then now we found out that even looters nowhere to shop. So. Bill gives some sectors where you think there's there's some value. There are still some value again. We've had this big strong. move off of the bottom. Here has the low hanging fruit been had or were you guys still looking here? Well certainly, the most extreme bargains have had a big mouth, but this is a historical change point so where they're still lots of value You know the banks were. She, as cheap. As, they were at the bottom in oh nine. But yet on a relative basis, just think how cheap they were. Then if they match price to book value similar back, then so wells. Fargo is all the way up to thirty three down from what sixty or fifty four highest right there..

Bloomberg Bill Cole US Max Nielsen Vonnie Quinn Robina Chris A. Bicycle SNEAD Miller Fargo Paul Stanley
"gilead" Discussed on P&L With Pimm Fox and Lisa Abramowicz

P&L With Pimm Fox and Lisa Abramowicz

03:28 min | 11 months ago

"gilead" Discussed on P&L With Pimm Fox and Lisa Abramowicz

"You're listening to Bloomberg. Markets with Vonnie Quinn and polls. Sweeney on Bloomberg Radio all over the last twenty four hours, bloomer news reporting about potential talks between Astra. Zeneca and Gilead two huge pharmaceutical companies maybe getting together in what would it be another healthcare emanate trade to dig a little bit deeper into that story? We welcome Max Niessen biotech format healthcare columnist for Bloomberg opinion as well as Chris Cues Christie's. He's a deal columnist for Bloomberg opinion guys. Thanks so much for joining us. Let's start with you Chris. Just get a sense of. Is this a deal that makes sense strategically, or is this more of a financially driven deal? Should something occur? There is no obvious it makes a lot of strategic. Accident occurred in the in the conventional. Thinking about deals both companies have got quite different sort of emphases in terms of You know the medicine say they make and faster than it has got a really enviable pipeline of Drexel Ready. It's one of the most attractive. Pipelines in the industry and I it's. Questionable. Why would want to do a deal? That might actually dilute the quality that that pipeline coming drugs, but as you say from a financial specter's starts to look more interesting, because out of really run at shaft price lately and not gives it good strong currency to. Pace a deal like this, and actually even though it's price, an attractive PUTT line drugs AstraZeneca's cash generation at this point in time actually isn't that great? Control with Gilead Guineas. Actually got some pretty good session the Russian. Put the two together. You actually have a a business financially has a much more. Solid price'll. Max would either of the companies have been looking to team up, and is there a chance that this might turn hostile at some point? you know I? I would feel a little bit surprised about that Wo- The likelihood of this actually happening still seems relatively slim to me. you don't kill Ya in its own right has had something of a of a pump up to its evaluation based when it's worth from desert. It might wants to capitalize on that I if I you know getting a return by by solidifying. That increase You know the fact that the currency would be so heavily made up of of Astra Zeneca. Shares is something that would make them quite resistant, and you know given the fact that both both companies are separately working on on different for a suitable efforts. Against the pandemic I I think they might WanNa avoid. Making this into a hostile fight. Max. Following up on that is there a the timing seems odd given that we're in the middle of pandemic. Here is any of this deal were centered around the science of somebody's gotTa drug or maybe put a couple of drugs together between these two companies, or if we put our resources behind is driven by the covid vaccine, potential or treatment potential. I don't think that's the case..

Bloomberg Astra Zeneca Chris Cues Christie Bloomberg Radio Max Zeneca Max Niessen Gilead Guineas Vonnie Quinn Sweeney Drexel Ready specter
Gilead says drug helped moderately ill coronavirus patients

NPR News Now

00:24 sec | 11 months ago

Gilead says drug helped moderately ill coronavirus patients

"California. Biotech firm is reporting some positive results with experimental drug remedies Aveer Gilead Sciences today reporting the drug when given a moderately. Moderately, ill patients hospitalized with covid nineteen shouted improved symptoms so far it's the only drug that's been shown to help. Fight the coronavirus, a large study down recently by the national. Institutes of health also found the drug would shorten recovery time for patients hospitalized with severe

Aveer Gilead Sciences California. Biotech
"gilead" Discussed on Your Brain at Work

Your Brain at Work

03:33 min | 11 months ago

"gilead" Discussed on Your Brain at Work

"As a sort of experiment at the time that if you have a virtual meeting in anyone's not in the room, then everyone's not in the room you know everyone's on their own individual zoom and actually found it incredibly productive. It addressed hall inclusion is. it addressed the by issue tons of distance by US and actually actually founded a great practice. We might find some organizations experimenting with that Oh. Actually, we're going to have zooms if if so that people don't feel left out and we had you know all of that. Yeah one of the things that we did you know because we're a global organization even before you know going the in the last couple of years as we have low colleagues that sometimes join us by phone sometimes video. But when they join us by phone, we actually place card with their name of around the table just as a way to recognize that are very much of the conversation even though you can't see them. Yeah. Thanks and just close off before we wrap up What's been most inspiring what's been most inspiring? Terms of what leaders of doing employees are doing, what's been most inspiring through this crisis at Gilead. Yes, I think I think for for us at it but Probably, for for many of us for us our our guiding principle in this is what is responsibility to the community to the patients into people in a Gilead has longstanding been a company that photos science rightly bring therapeutics we are in the business of really you know helping save lives, improve lives. So one the concept of people putting the larger purpose before the personal concerns has been as deeply deeply inspiring right at so many levels and second I. Think it's inspiring to see you know how we are responding to our responsibility both externally and internally. And in a very real authentic way I mean I think this is hard to make ripe you you can't really pretend to care and what's been really great to see here at Galeote's the true sense of care the.

Gilead US Galeote
"gilead" Discussed on Your Brain at Work

Your Brain at Work

05:09 min | 11 months ago

"gilead" Discussed on Your Brain at Work

"Virus vaccine showing seem to be safe on eight people ranging from ages eighteen to fifty five. This news was the first glimmer of an answer to the question that a lot of us have been asking. Will we ever get vaccine. The people working hard within these organizations, the operators, the chemists, the team leads these are the ones doing the innovating, and it's on top of the already important work. They're doing to develop better drugs to fight cancer and other diseases. So, as they work hard to help us. WHO's helping them? I'm Chris Weller and you're listening to your brain at work from the Neuro Leadership Institute. For the episode and the ones that follow will be drawing from a weekly Webinar series that has been hosting every Friday between our co founder and CEO Dr David Rock and two distinguished guests. In today's episode, you'll hear from JOE MIRA CHR of Gilead Sciences and Doug Pinski head of leadership development at Merck. Discussion. Focuses on how Gilead is creating a culture of empathy through leadership forums and developing common language. And Merck is meeting people where they are to keep learning development going strong. Enjoy. Thanks very much Iran for joining us jody and Doug thanks a lot for being here with us. Jodi will hear from you I as we explore a tapping over. Gilliat. Very a very public organization right now with disappear, and then Doug will come to you with Merck and those if you don't know mercury in the vaccine business who get about that a few months ago now he seemed to okay a lot about it. So we can hear a little bit about what's happening in that? World. So thanks both of you for at for joining us Johnny Join me here we'll have a conversation and I and I have to kick off with saying thank you for everything that you're doing there over a gilead sciences and making time for us given what an incredible incredible you know situation you guys in public is well I. Know you'll have to all of you know people talent at Tequila Addin. Thank you for training me half as Abram disappear as well. Last time we we connected that was great. Thanks for everything that you're doing and you know how how you guys doing over there what's the? What's The vibe over? Care about first of all, thank you for having having a me join this morning with the colleagues from all over the world and a very warm morning. Good afternoon. Good evening to all of you see all joining us from different parts of the world. So delighted to be connected with you and it is You know we are a here. Get it. You know we are filled with pride Gilead as many of you know his is a biotech company life science company that is really a leader in the antiviral space and we are feeling by very fortunate that you're in a position to vity. Explorer are investigational drum desktop disappear as did talk to out and did it be inability to bring back out to the communities, enter the patient? So our teams working incredibly hard. You know that are investigator ever since the outbreak of this crisis in pan-demic at the beginning of the year, they have been headstone. Ready, thinking about what more can we do scientifically and those teams that are not working on her disappear are really coming to support these teams I in helping in all other ways possible. So it's been it's been terrific. Our Purpose Corpus Awadhi exists in the world we do has never been walked larimore himself..

Doug Pinski Gilead Sciences Merck Gilead Abram Neuro Leadership Institute Chris Weller JOE MIRA CHR cancer larimore Jodi Tequila Addin investigator Dr David Rock Iran pan-demic co founder Johnny vity jody
"gilead" Discussed on WTOP

WTOP

02:44 min | 1 year ago

"gilead" Discussed on WTOP

"Are authorized to Gilead's application for emergency use authorization for the use of rent does appear in hospitalized patients that was issued today stay at home orders have worked to reduce the number of virus cases in Pennsylvania governor Tom wolf says they'll start easing restrictions in a week today I'm announcing that for next Friday twenty four counties will have some cold nineteen mitigation restrictions lifted New Jersey governor Phil Murphy okayed some outdoor activities as of today as we re open our parks in as some of you head back to the golf course social distancing is going to be the watchword we will be closely monitoring actions across the entire weekend CBS news update I'm Pam Coulter five thirty two if you get sick with corona virus would you want a lawyer at your bedside in this case you'd be smart to because she went to nursing school as well she's been nominated as a frontline hero and wins a hundred dollars from WTOP and northwest federal credit union theory I was just supposed to cover people's vacation but in the pandemic Esperanza Sanchez of northeast DC has been working weekends as a nurse on the rapid response team at the George Washington University hospital it basically is a team of ICU nurses that we respond to in house emergency so it's like your in house EMS she's doing it on top of her day job as a lawyer at the department of labor where she's worked on guidance to protect workers from corona virus she says treating COPD patients is tough work but has its upside we have seen several people get discharged home like the joy you feel pure and utter joy John Aaron WTOP news the Senate will be back in session Monday but some lawmakers don't think that's a healthy choice during the pandemic more from WTOP's Capitol Hill correspondent Mitchell Miller today on the hill Maryland senator Chris van Hollen as outlined concerns that are shared by other democratic lawmakers in a letter to Senate Majority Leader Mitch McConnell van Hollen notes that the Washington area remains a hot spot for covert nineteen name also pointing out that at least eleven workers at the cannon house building have tested positive for the virus McConnell has assured that appropriate safety precautions will be taken as for the house speaker Nancy Pelosi says they're still working on proposals that would allow lawmakers to vote from their districts by the time we do come back we will be able to vote on remote voting by proxy because you have to have a vote to make these changes hello see hope the house can return the week of may eleventh on Capitol Hill Mitchell Miller WTOP news some major problems for the purple line we'll talk about it coming up it's five thirty four northwest federal credit union honors the frontline heroes who are guiding us and inspiring we know that you are serving on the front line for your family striving to provide determined to protect.

Gilead
"gilead" Discussed on Squawk Pod

Squawk Pod

09:59 min | 1 year ago

"gilead" Discussed on Squawk Pod

"Easy. The back of your are not far from this music. Lesson Assign Company adjusted the shutdown. You still kind of like most Americans father saying. When are we gonNA wake up from this nightmare? We were really grown at a rapid rate and it just stopped every other phone call was. We tried to stop supplies. We tried to stop everything to try and preserve the cash flow just decided to sprinkle them around town and we really wanted to do it under the radar. We just want it to be something I would see and also around the corner. A fifty year. Old Pizzeria is doing take out. Only day'll be named those in my guys. She thinks her relationship with customers is. What's keeping her business going. During the outbreak we watch you. GotTa Take Care of the employees. You got hunker down and try and get through this. We're all in it together but we really are at the truth. Which throwing hand. We wish all of them well that was. Cnbc's Andrea Day reporting and over. The coming weeks will keep bringing you these stories from Main Street in crisis. There is more ahead on this. Cnbc special report markets in turmoil. It's really a opening the door to the fact that we now have the capability of treating next tonight one prominent doctor on why he isn't nearly as optimistic as so many other. Americans on the possibility. Gillian's drugged gets us out of the woods and feeling a bit of a thaw and to work towards by early June planned to have over ninety percent of our stores open in the US. Some of the biggest names in the C. Suite sounding off about what's next for the American economy this CNBC special report markets in turmoil is coming right back. The data shows that run DESA. Has it clear? Cut Significant positive effect in diminishing the timeline to recovery. This is really quite important but not everyone agrees tonight. One doctors cause for concern plus one pharmaceutical executives path. Forward to prevent a national antibiotic emergency this. Cnbc special report continues once again. Here's Scott Wapner. It's going to have you back with US following a big jump for stocks today. Strong earnings after the bell from Microsoft and facebook have the futures higher right now. The Nasdaq go at the bottom would open higher by more than one hundred points right now by the way if that happened as that would be positive positive for twenty twenty thus far today stocks rallied after positive news on Gilead potential virus treatment. The Dow rising more than five hundred thirty points the S&P five hundred up more than two and a half percent having its best months since one thousand nine hundred seventy four. By the way small caps were strong again today Russell. Two thousand up for the sixth straight day but a long list of chief executives on this network today tonight where their company stand on the virus the American economy our path forward? I think we can achieve kind of stability and maybe even better stability than we had free virus simply because of the reduced rates. I'm feeling a bit of a thaw and I'm hoping it's in. Continue to work towards reopening in the first quarter. We saw a little bit of soccer. China's were shutdown. That's now come back a bit here in April but I would say all things considered. We're we're very fortunate that we're in markets where people need more computing. So that's that's really our focus starting next week here in the US. We are going to open a significant number of starbucks stores by early June planned to have over ninety percent of our stores opened in the US. We're talking about something that has billions of consumers around the world that are now moving their behaviors online something like the Cova will likely accelerate that trend for us where religious in the growth stage of trying to capture that growth. I think traffic will continue to improve and I don't think we need to have you know the calming Dr. One hundred percent to have a reasonable returns again. Subways are much smaller. It will be a challenge in a thousand ways right as we rethink the way work is performed in factory at a job site in an office But again safety will be the overarching priority here. It was positive news on. Gilead drug that gave those CEOS and investors. New Hope Today but Dr Jeremy Faust who's been with us at seven PM since the start of this crisis warns about moving too far too fast. He is with us once again tonight. Doctor Faust Welcome back good to talk to. You could be here. You're not as optimistic about Rim desert. Some others are today. I think that we are seeing a slight glimmer of hope here but I worry that the exuberance is related to an old saying that there's no sauce better than hunger and we want something so bad that even something that looks a little bit promising is getting blown out of proportion in terms of what it means for the number of lives that we're going to save here why so well in particular the studies that are going around the Internet today that we actually haven't even seen the studies they actually change up what they were looking at so initially the company was trying to detect. If this medication would save lives bring people off ventilators but instead actually at the last minute they change their mind and said well. We can't look at that. We're just GONNA look at of the patients who went home. How quickly did they go home? And I think that's actually an important thing that they found that they found. It looks like it's going in that direction and we can talk about. Why but it's not the game changer. You don't believe what Dr Chee had to say. Today in the Oval Office. You just said things that are going around the Internet this came from Dr Fallacy directly today. I I shouldn't say that Dr Fouled. She is saying that he's seen results. And so it's those aren't rumors that's correct but what I mean is. The interpretation of them as being is being a little bit more substantial in terms of athletes going around and stock prices. Going UP. Not Sort of thing. I think that Dr Found. She has been through this before with HIV and he sees when a drug shows any glimmer of hope. That's a great sign because it means that we're at the beginning of a story but not at the end of a story so I understand what where he's coming from with his optimism but a measure. Because what we found so far is just a little piece of the puzzle understood. No one's suggesting it's a panacea but you would submit that it is a step in the right direction for therapeutic. It appears to be. We have to that study. But at the same time we got data today from the Lancet which is one of the most prestigious journals in the world and they did a another trial which was also both of these studies to be very well designed and that study shows absolutely no clinical improvement and again. It's that's a big disappointment. Because you WanNa see something that saves lives now. Getting people home sooner actually. It does have a benefit. It's not just a number. It means that we could patients. Of course WANNA go home sooner. It means that we can have less P. P. E. at the hospital burn through and it's less expensive possibly. It's there's a lot of good things about it in terms of capacity but again it's I. I was rooting for some kind of mortality. Benefit would would you well? The mortality rate was lower in those that were given rim desert versus placebo. It looks like there is a non. Well there's not a statistically significant effect in that in that direction so again by the way it looks like it might be close so I'm not going to say that there wasn't one but I will say it was a pretty small benefit. Looks like and so you would have to treat twenty or thirty patients to save one life again. That's a big deal especially if you're that one life and I think that this is the beginning of does. This doesn't medication like this as a medication. Like this in collaboration with another medication work. This is the beginning of trying to find something that will have that robust large mortality benefit that we are all after to be clear. Would you prescribe it? That's a very interesting question. I think that it would depend on the situation. I think that we absolutely have to look very carefully at who which patients receive this drug in. Which patients did not so when the trial is actually published a journal? We get to look very closely at who? What the demographics the ages. How sick they were and how sick they weren't and if if if all the shows is that it was safe and that people went home sooner than yes. I would certainly give it some patients. But you are. You're not sitting here this evening. Saying that's steadfastly. You would give this medication to Cova patient. Who was in your hospital? Who was terribly ill. It's really hard without seeing the data. Yeah wh Dr Fallacy said would lead to believe that I would but again we have to see these data and see what they mean and to know which patients applies to. Because we're going to have a supply issue as well so we want to make sure that I would definitely give it to the patients who benefited from it in this trial and make sure that I didn't give it to anyone who might have helped or it might have heard. And so. That's what being in the clinic on the front line like I have to do. I have to say what works. And for whom and when. It's very complicated. So if what we're hearing is true and I think it is I would say yes. There are going to be some patients who should receive medication. Because I'll get them home sooner. I would go with that doctor. Faust good to have you as always. We'll talk again soon. Thank you Dr. Jeremy Faust with US tonight from Boston. There's more ahead on. Cnbc special report markets in turmoil. Many parents ready for the students to go back to school. But are the teachers ready before the break images from around the world on the one hundred twenty second day of the pandemic.

Cnbc US Dr. Jeremy Faust Rim desert Cova Old Pizzeria Doctor Faust soccer Dr Fouled Dr Chee starbucks China Andrea Day Scott Wapner Microsoft Gillian Russell
"gilead" Discussed on Squawk Pod

Squawk Pod

02:05 min | 1 year ago

"gilead" Discussed on Squawk Pod

"The. Ibm Cloud is the cloud. That's open that secure. That's built for business. It's also the cloud that's leading the way but don't take our word for it. Chuck Gardner Peer Insights to see why customers rate IBM cloud of of AWS. Google cloud and Microsoft Azure over the last twelve months as of February. Twenty Eighth Twenty twenty. Ibm Let's put smart to work. Gardner peer insights reviews constitute the subjective opinions of individual end users based on their own experiences. And do not represent the views of Gartner or its affiliates. Welcome back here. Are Tonight's headlines on Day? One hundred twenty. Two of the CORONA VIRUS CRISIS LIFT is laying off one thousand employees that seventeen percent of its workforce and furloughing hundreds more as demand for ridesharing. Plummets yesterday it was reported. That Uber is considering laying off twenty percent of its staff Texas Tech and Alabama. Both say they plan to have students back on campus for the fall semester news from the National Pastime Tonight Major League Baseball postponing this year's hall of fame inductions running a business as you know on Main Street in any American town is challenging even in good times but trying to keep it alive during a pandemic tests. An entrepreneur in ways most never imagined. Cnbc's Andrea Day tonight on three business owners from one long island town who candidly share their struggle to find a path forward with main street in crisis. Washington is really close to ending city. But you would never know it. It feels like any other small towns with an incredibly close knit community. When this corona virus hit we literally hit a brick wall and just had to stop immediately we are full service. Music School. It's had a tremendous impact on us. We couldn't figure out how to apply a band to zoom virtual session. Our Band program is almost fifty percent of our revenue. It dropped tremendously thousands and thousands of dollars.

cloud Eighth Twenty twenty Chuck Gardner Ibm Gartner Andrea Day Baseball Texas Tech Google Washington Cnbc Microsoft Alabama AWS Music School
"gilead" Discussed on Squawk Pod

Squawk Pod

07:45 min | 1 year ago

"gilead" Discussed on Squawk Pod

"Think in the same direction. Well you get more clarity when delayed releases results from its own trials. That's certainly true. There's there's three studies underway There's the NASD study. That trial met its primary endpoint. There's GonNa be more later today. from I think I believe Dr Fao she at a press conference there is also and I'm getting this right now. there's also Data that's going to come out from the Open Label Studies. They kill you. It's been conducting non randomized studies. But I think maybe we have more news on on this meg view. You have a different study or just more analysis of this one joe have exactly what Dr Godly was just referring to you and I assume he was just reading the press releases. I was just reading because Gilead just put out. Its own study results so that was the one we were expecting today. This is in severe patients with cove. Nineteen and as we mentioned it was an open label study and it was not placebo controlled so the data are difficult to draw obvious conclusions from the top line. Is that the five day and ten day dosing. Regimens appeared similar in this study. And Gillian says it's a compliment to the study. Met Its primary goal and that one was placebo controlled so the NIH results are the ones that are going to really tell us how well this drug worked. But what Gilead is saying here. Is that those two dosing. Groups regiments did appear similar. So that could increase the supply of the drug. They're also saying in the release here that earlier treatment did appear to be better for patients they say patients who received from desert within ten days of symptom onset had improved outcomes compared with those who received after ten days. They say pooling data across the treatment arms by day. Fourteen sixty two percent of patients treated early. We're able to be discharged from the hospital. Compared with forty nine percent of patients who were treated late of course because this is not bliss evoke controlled. We don't know those patients would have just gotten better by themselves. And if the impact of earlier treatment could have been influenced by other things. So that's why the results are going to be so critical to hear later today. Guys one one added piece here and I'm getting this right now so Coming across to me but I think that there's going to be a press conference later today with Tony. Fao going to talk about the NASD results. So it's possible that if that trial really does show a trend towards Positive outcome here Fda could authorizes under an emergency use authorization or under an accelerated approval fairly quickly But I would expect them to have a press conference so to provide more information later. Today you had said earlier. The good news is the five day treatment is just as effective as the ten day treatment that that means twice as much of this drug to go around but Meg d you or Dr Gotlib. Either of you know what kind of supplies we have for. Severe what kind of numbers. You could be seeing how quickly things could ramp up in order to get more of the drug made. Yes so Gillian has put out. What the supply it expects to be able to make is by. May they expect to be able to supply one hundred forty thousand doses of the medicine? But that's at the ten day regimen so if they can cut that to a five day regimen for a lot of patients that will significantly increase that supply. That's not a huge amount of drug. The company is looking at reformulating it into potentially oil deliverable drugs so into pill or into an inhalable drug. But that's not a slow process. I'm sure Dr Gotlib. We'll have more insight on that and on the potential supply and ways to increase that quickly than I would. So how long would that is that difficult to do? An oral formulation Dr Oil formulation would be difficult here because of the complexities in manufacturing this product. I think that there is some speculation that you can develop a nebulizer and inhaled formulations of this drug. That could potentially be efficacious as well but right now the issue is just GonNa be ramping supply. Gilliat it's been working with a lot of contract manufacturing organizations to try to increase supply but it's long manufacturing process at the complex drug manufacturers. So we are going to be supply constrained. I do think you're going to see more information coming very shortly from federal agencies and from the company talking about these results today and then talking about the process going forward and how this could be made available more broadly either under accelerated approval or more likely under an emergency use authorization which would allow commercial distribution of drug to make make sure more people can get access to it in a setting of the current epidemic. Scott where where is manufactured Menu I don't know for sure is the answer but it's manufactured at multiple contract manufacturers right now. I know that the company has been working with a lot of different manufacturers. And so it's not a single location where it's being it's all being manufactured says here and it's really about supply that it is increasing capacity with partners. North America Europe and Asia. And I think that probably gets to your question about the importance of where things are made to be able to supply. Kits will you had that op Ed in the Wall Street Journal or this week raising concerns about even if a cure or vaccine is developed at not having it manufactured here might mean that Americans. Don't get it I yeah. I don't think that the entire manufacturing processes totally within the United States right now they might be components of of of it or there might be some supply that you can do totally within the US. But I think aspects of the supply chain for this drug. Come from other parts of the world to your point becky. So you know that's why it. Gilead has worked globally to try to make this drug available particularly in China where I think. Some of the supply chain originates but The company's been working in the United States government. I think has been working to try to domesticate. More than manufacturing increase supply here. It's a complex drug to manufacture So you know. In some ways it's not an optimized drug it's can't be formulated into an oral agent very easily complex to manufacture it needs to be delivered intravenously. It does have side effects associated with it. So it's not a perfect drug what it is. It's a drug that was on the shelf. It's the first generation at the viral against Corona virus that can be effective for a certain number of patients. This is not a home run. I'm a cure by any means but I think that this can be very effective in the context of better treatment for patients a better understanding of how to treat these patients and hopefully other drugs. They're gonNA come onto the market in the fall. This is part of the better toolbox. We've been talking about better testing better treatments Dr. Do we talk about the time line with you? All the time. And the ability to try to give confidence to Americans and frankly those all over the world to go back go back to work to go back to some sense of normalcy and we've talked about a possible vaccine bringing that kind of sense normalcy. How does this change the dynamic? Meaning do you think that this drug based on what you know will create the kind of confidence and win. That people would say themselves. You know what? I'm maybe I'm willing to go out. Go Out and do what I'm GonNa do and if I get this. I'll have the confidence to know that I can take this drug and things might be okay. Is that yeah? We'll come into place. I'm in the same place I've been when we've had this discussion many times. Which is this drug. Coupled with the therapeutic. Antibodies ARE UNDER DEVELOPMENT BY REGENERATION VEER BIOTECHNOLOGY. Amgen and lily coupled which with much better testing that we're going to have the ability to millions of people week heading into the fall. I think that that could be a robust toolbox. That could mitigate the risk and help help reduce the fear. That if you get this that that is a race to the bottom that. There's nothing there to help you. We're also learning how to treat patients with covert much more effectively in the hospital learning what interventions to do and not do so. I think all of this is gonNA put us in a much different posture. For the fall. This is a part of that toolbox. We talked about that could reduce the risk of fall and allow us to get back to some semblance of our normal lives even with covert circulating in the background. Dr Gotlib Meg WanNa thank you. All especially Dr Gotlib and meg for getting on so quickly with that breaking.

Dr Gotlib Dr Gotlib Meg Wan Gilead NASD Gillian United States Dr Fao Dr Godly Amgen joe NIH Wall Street Journal Fda Tony North America Asia China Scott
"gilead" Discussed on P&L With Pimm Fox and Lisa Abramowicz

P&L With Pimm Fox and Lisa Abramowicz

14:33 min | 1 year ago

"gilead" Discussed on P&L With Pimm Fox and Lisa Abramowicz

"As well as at Bloomberg Dot com well one of the things that investors are looking for when I think about this pandemic and the krona virus is what is going to be the role of biotech and big Pharma in coming up with some treatments ultimately a vaccine. There's some decent news out of Gilead Sciences. Today they may have they may be onto something to give us a sense of kind of where we are with the healthcare system and the biotech companies in a Pharma companies who welcome our good friends. Santas L. Sanford Elliott director research for Bloomberg Intelligence. But more importantly his day job. He is one of the top healthcare analyst. He's based in London so Sam. Thanks for joining us. Give us a little sense of what the news was out of Gilead. How IMPORTANT IS I? Hope you're old well So obviously we've got to bits of news that have just come out what. Gilead self put out was a trot tested the done to try and see where they're five days of the drug is as good as ten days of of drug. Obviously nobody wants to be going in for a daily infusion of drug more than they have to so in that study that day reported which wasn't very severe patients. Apparently five days was just as good as ten days. A lot of people netflix. Read between the lines and look at the number of patients who recover didn't recover and trying to understand whether the drug works from that trial but of course he wasn't controlled and you know what what our motto is if it's not controlled if he's not randomized. You really have to wait until you see that data. The other major news is this headline thing that we've seen nothing. Max talked about earlier on the radio too and that was that the national shoot for Allergy and infectious diseases has got this trial that is randomized as apparently worked in four hundred patients. And it's going to be some data on that now that's a proper trial testing ten days with a distributor. So the problem is we just don't know what the data is taking a step back. I want to understand the importance of Rim desert being successful in other words. How broadly can this be used? If it's something that has to be administered in a hospital like setting for only the most severe patients is it a game changer. When it comes to the pandemic what a great question at the end of the day. I think we all love to have a single game. Changer I would be very happy to see this drug. Be that single game changer. What he's not going to help you and I sitting at home feel secure to go out. All we know. Is that any of these drugs that are being tested for drugs. That are going to help us. Hopefully get better faster without suffering too much once. We've got the disease if we get the disease. So that's what they're all being tested for rush drug. The Pfizer drugs the astro drug the regeneration and Sanofi drugs to make us feel really good and game. Change everything you still need that vaccine that gives you protection. So let's go there Sam. I think you know a lot of the officials that we all hear about what the government officials or health care officials. They seem to have kind of coalesced around this twelve to eighteen months timeframe for coming up with a vaccine to me. You know just having a little bit of experience. That seems very short. That seems like I'm more used to a number of years. Give us a sense of how you think. The timing of a vaccine might play out right so I have to continue to be humble here in that. I haven't been in a lab with my hands for twenty years but the and you listen to a little scientists a lot of top scientists from the scripts institute from Oxford University and they all are very optimistic given what they know about the virus not all viruses. Thank God created equally and I heard one virologist if this was on the scale of HIV being ingenious this is one that flunk type school. Thank goodness I am glad to hear that Immune System. I love that comment. So if that is true and technologies will work with the with the Everything that's being thrown developing vaccine with all these companies ranging from biotechs to the big shots in Vaccine Business Pfizer Glaxo Salafi and Merck I hope that they are right. But you still have to get everything has to work out for this to be to be successful with that sort of timeframe. San There's also a question of the pipeline of production here and how quickly once there is a vaccine it can get mass produced and distributed to enough people to get some sort of herd immunity. What do we know on that front in terms of the cooperation internationally with say what's going on an Oxford where they're starting human trials so Oxford seems to be doing some interesting stuff here in there? They're not really necessarily interested in being a vaccine company themselves. You know just sort of a an announcement today that the Serum Institute of India is going to produce their vaccine and they're thinking of well. We're going to do that. We're going to keep it for India. I'm assuming vaccine if it's successful would be available to whoever wants to take it on and manufacture it so I wouldn't be surprised to see more countries or more companies from different countries coming up and say right. We'll have a go at that but at the end of the day with regards to national politics versus Vaccines and manufacturers. What I think what we should have to do is just wait and see who can actually get that stuff done and then worry about how it's going to get spread out if you think about the volumes that these countries talking about will have like two billion doses of vaccine next year at Johnson and Johnson to collect so to Sanofi to Pfizer is a big number. So I don't think there'd be a shortage Klay really so SAM. What are some of the next milestones? We should be on the lookout for us. It's just company by company putting out kind of their tests or anything more. I guess maybe centralized That we should be looking for from the treatment of vaccine side of things That we're talking about. We have in the next three months. There'd be lots of data points coming up. Starting hopefully with the data the actual data safety and efficacy and safety again safety remember. These are a lot of these vaccines are GONNA have to go into people who are not sick. She can't give them the risk of an ailment For the next two to three months we'll hear a lot of proof of concept is the best place to call it for Vaccines Pfizer very cleanly described. Some of the methods are going to use to figure out whether they think something that they've got is Protective Potentially And then you've got the drugs that will reader. Rauch will have read that in early Summer June. Time for a drug. You've got that will have some data maybe later today or certainly in the next few weeks they asked Zeneca. We've called Queens. Then you've got five with these anti-virals so there's quite a lot of news that I think we'll be sitting here on a weekly basis hopefully talking to each other about success. Well hopefully we will get a chance to speak with you again. Soon Sampras. Ellie had of the E. M. E. A. Bloomberg intelligence effort as well as a senior pharmaceutical analyst really helpful insights to understand the progress being made looking for that silver bullet to allow life to.

analyst Gilead Sciences Bloomberg Dot Gilead Bloomberg Intelligence Vaccines Pfizer L. Sanford Elliott Johnson netflix London Serum Institute of India Allergy Rim desert San There Oxford India director Oxford University Zeneca
"gilead" Discussed on Snacks Daily

Snacks Daily

09:50 min | 1 year ago

"gilead" Discussed on Snacks Daily

"Peace globally instability. Yes it would four. Our second story Unilever's earnings report. It's a it's a mere into your life is a window into your soul. Also Jack and I pulled this thing up. It is the most artistic earnings report we have ever seen. I'm thinking about stealing the Color Palette for my future home whenever I actually own a home. Whenever artist is whipping this thing up is probably the thing. Go to the Harry Potter illustrations. They got the same whimsical vibe. Going on it's a European thing. You should check out this deck. We'LL TWEET IT OUT. Snacker now some companies give you a taste of an industry. Think about yum brands they own KFC Taco Bell and Pizza Hut if you know yum brands you know what's going on. In fast food other companies can give you a reflection of an entire economy. Can I just love this stat? Ninety percent of Americans live within ten miles of a wal-mart which sells everything. So if you know what Walmart's doing you kind of what the American economy's doing unil- ever on the other hand is bigger in scope. It is a mirror into the world of retail spending. They've had to buy those little folder for passports. This company is dual headquartered in London and Rotterdam Rotterdam what is Rotterdam just like an Amsterdam cousin. No one really knows what it sounds like. An off breed rottweiler. But I don't think it is. It's like the Narnia Holland. The diversity you will find you'll ever sales. Seventy percent are outside of North America in South America. They're all over the world and then don't forget about unil- ever size. They did thirteen point. Four billion dollars in sales last quarter which is about one half lifts also make like everything from Helmand manifested Dove Body Wash dollarshaveclub shave club to cue tips and Lipton ICED tea. That just destroyed by Tom. There are five cents is on your body. Guaranteed one two. Three of them are touching something that was made by Unilever today. So you'll ever earnings report was fascinating because they reveal how work from home which is happening. Globally is shifting the world's buying and usage habit. And then what we was extra fascinating was how they break down. What's being hoarded right now? And what's actually being used? Let's start with shampoo. That's a whole division at Unilever. What they told us is that shampoos. What they told us is that shampoo sales are up. People are calling it but they're using it less deodorant sales same thing it is being hoarded aggressively. But it's being used barely. In fact they went into detail about how little it's being used. Take personal care. Products for instance like Shampoo Deodorant. We are buying a lot more vet. Because we're all like hoarding and filling up our pantry. But we're using personal products on average eleven times fewer per week which is Kinda Gross. Let that sink in. That means three. Fewer Deodorant swipes a couple less conditions. And let's be honest Wednesdays or no Shampoo Wednesdays. I mean no one can smell you. Zoom in the meantime. There's another funny thing. Is You get to know about Unilever? It is. The world's biggest ice cream visit has a lift worth of sales every year in the brands like Magnum yet. Briers Ondeck popsicle and Vermont Favorite Ben. And Jerry's you can throw anything into a ben and Jerry's it's not gonna be as good as just Ben and Jerry's interesting insight about ice cream. Sales about half of them occur at grocery stores but the other half occur on site in like a scoop truck by Venice beach. And that's kind of problem because right now you're getting none of that scoop truck by Venice beach. So there's a cease Afaq sales at grocery stores are up but sales outside of grocery stores aren't happening period. So Jack what's the takeaway for our buddies over Unilever in Rotterdam half the time? There's a big pivot in retail for this crisis and is cutting out the middleman. Move over Harry's and Casper there's a middle aged Dutch guy who wants to go direct to consumer over here today. Big Old Unilever relies on retailers like Walmart to actually sell the products that it produces and the krone. Economy is showing unil- ever that it can successfully cut out that middleman. Nick and I found this one shocking. Apparently six percent of Unilever sales or online at like Unilever Dot Com. Whoever's buying shampoo you'll ever dot com revlon but online sales for Unilever jumped by thirty six percent last quarter that's direct sales to you from looney. Unilever. They want you buying up treasuries cup a soup on their websites. That's right Unilever wants you buying from Unilever dot com instead of Amazon dot com snacks challenge. Update were little over halfway done. So if you're running a loop just keep running. Can you'll get all of. It always works for our third and final story. Gilead got everyone excited to start the week but then a new report made everyone very sad. Carolina feels like the classic throwback entourage episodes on this video. Doing the movie got hurt. He's not doing the move on Friday last week. The University of Chicago Hospital was hopeful about this drug called Rim desert. Yeah interesting name very confusing. Sounds like it's made by Unilever but it's actually produced by Gilead Pharmaceuticals and was really effective in treating like one hundred twenty five Kobe. Nineteen patient. Could this be the one? Could this be Kiana? Is it red pill or blue pill? They're like oh it's both Pales Kia. Investors wondered if this could be the one that helps us end this cove nineteen crisis although Gilead and like a bunch of science experts. Who Poke the brakes on this one guys? Don't get too excited. We're in early stages on this thing and then Wall Street got too excited. Excited actually surged after. This early report gave hope to investors that this could eventually fix crisis and reopened the economy. That was way too overly optimistic. The news from yesterday another more robust clinical trial for Rendez aveer shows. It's actually not that effective cure and covert nineteen and just like. We told you on Monday. This is also playing out just like a screenplay. It is a tale of two clinical drug trials. This Chicago trial was a small data. Set One hundred twenty five patients. Isn't that many and on Thursday? Somebody accidentally published an early report on a bigger and better study. That was way more relevant than that. I won't rewind to January when the covert nineteen outbreak was like devastating China. Gilead recognized an opportunity to test rim desert and see if it was useful in treating unfortunately when they did this early test in China. The drug showed no benefits and that was on twice as many patients summer. You had a small study in Chicago. That showed good results a bigger study in China that showed bad results now gilead still says the Chinese study showed like some potential benefits so more studies are coming while we're waiting for those studies Jack. What's the takeaway for our buddies over? Gilead the power of a control group. This is the old. Ab Test snacker. Jack Burns his tongue. I could feed him some nice cool milk from that. Dangerous Thermostat had burnt him a couple of days later. Jack's tongue miraculously gets better at it. Was the thermostat cured. The awful the flaw however in that thinking my tone would have got better without the milk and without the dangerous thermos that I should probably throw away. The Best Studies include a control group and a treatment group. Shyness study did this. Chicago's study. Did they randomly gave the Chinese patients? The drug or like a sugar capsule that looked like the so. The Treatment Group got the real drug. They got Ram Desert and the treatment group. Fourteen percent of them ended up dying and in the control group which didn't get the real drug. Fewer people died in fact only thirteen percent. That's the opposite of what you would hope that. Remm desert would do pretty much means that we cannot reject the no hypothesis. Drug wasn't effective intriguing. Covert Nineteen Jack. Riyadh that tone. Whip up the takeaways force over there. Raytheon just WANNA stealth nuclear tipped cruise missile governments that would splurge on stuff could be running some debt problems right now. I said can throw a UTAH. Evers earnings reveal that. Were buying more personal products. But we're actually using them. Less even conglomerates are going direct to consumer since stores are closed third and final story. Gilead had to study so far about whether Rim desma fear can effectively treat. Cova one thousand nine patients. This smaller worst study says it's effective. The bigger betty study says it's not unfortunately now time for our snack fact today this one. It's simple it's straightforward. You're GONNA love it. It's from Richard B. and Bristow Oklahoma in Chicago. It's illegal to eat in a restaurant. That's on fire in Marion Ohio. It's illegal to eat a doughnut while walking backwards. I always wondered if these things are really true. Are the April Fools Jokes? That just never got erased. It's the most creative thing legislators have ever done. We also WANNA give a shoutout to Maria. Yes turns thirty on Sunday. Your husband Graham had a big birthday party planned for you this weekend. It was going to be awesome. That got cancelled. Obviously so he's giving you a snack daily. Shout out instead grand. Whatever you do. Don't give her a thermos and please stay bark to your poppy. Remmy she sounds adorable. Snacker loved being with you this week. You looked fantastic by the way we should point that. Share your favorite bite from today's snacks on social buddies because it helps us grow. It's how we grow if you know you know. H Wyatt y EST Monday the Robin Hood. Snacks podcast you. Just heard reflects the opinions of only the host who are associated persons of Robinhood Financial Llc and does not reflect the views of robinhood Markets Inc. Her any of its subsidiaries or affiliates. The PODCAST IS FOR INFORMATIONAL PURPOSES. Only and is not intended to serve as a recommendation to buy or sell any security and is not an offer or sale of a security. The podcast is also not a research report and is not intended to serve as the basis of any investment decision robinhood financial LLC member Finra SIPC..

Unilever Gilead Chicago Jack Burns wal-mart Unilever Dot Com Snacker Harry Potter Rotterdam Rim desert Pizza Hut Robinhood Financial Llc Venice beach Magnum Rotterdam Rotterdam Vermont Robin Hood Gilead Pharmaceuticals Treatment Group
"gilead" Discussed on KCRW

KCRW

02:43 min | 2 years ago

"gilead" Discussed on KCRW

"Her confronting Gilead shareholders Gilead has the power to. Crap available right now for everybody and they're not doing it. In a statement, the companies hold NPR it, quote respects the work of HIV advocates and has been engaged with the advocate community for decades, but that price tag remains the current list price, one thousand seven hundred eighty in the United States CEO Daniel o'day testifying about this issue on Capitol Hill, a few weeks ago, Gilead is the only company making this drug in the US right now it's under patent for a limited time and shareholders, wanna see profits the pricing said in the United States takes into account. The innovation brings the cost of the healthcare of trading in HIV patient, the ability to invest back in research, and development, and then also to make sure our access programs are affected Gilead argues the price isn't the problem. Lack of awareness, stigma, and homophobia are the problems. And they say few pay the full list price Gilead provides the drug at a discount to government programs. They just donated drugs to the CDC to cover some. Uninsured patients, and people with high deductibles can use its co pay assistance program prep for all activists are dismissive of these efforts in Jake Powell's case because of personal experience, killiadts copay assistance program. The first year paid out the full cost of those first few months to the point that my insurance, then kicked in and paid full price for outta the next year pals insure stopped counting Gilead payments towards the five thousand dollar deductible Powell would have had to pay out of pocket for six months because I couldn't afford. It was really frustrating. Definitely scared in a way that I was used to not having to be scared prep for all says to Gilead. You've made billions already just lower the cost of the drug to the government prep for all says the CDC can come in and reduce the cost of prep prepping provided an affordable price. That's Emily Sanderson again activists make two points that the CDC has its own patents for prep. The agency could be enforcing something Gilliat disputes. And that taxpayer money. Was used in the studies underlying Gilead true patent. The government has the power under the by dole act of nineteen eighty they argue to March in and break Gilead patent in the name of public health and let generic competition, bring the price down. This prep pricing issue is a fixable problem, and we can get to everyone who needs it. Neither the CDC nor Gilead have shown signs of being moved by these arguments, if the activists don't convince them to act, the one million people at risk, for HIV, we'll have to wait until Gilliat true patent expires next fall. And then wait again for generic competition to possibly lower the price closer to that five dollars a month, people get in.

Gilead CDC Jake Powell United States HIV Daniel o'day NPR government Emily Sanderson CEO Gilliat dole five thousand dollar five dollars six months
"gilead" Discussed on WiLD 94.9

WiLD 94.9

04:16 min | 3 years ago

"gilead" Discussed on WiLD 94.9

"Gilead i'm peter oh come on yeah groceries three everything the modern bows jason compete balls man say soon never sorry z just like mommy.

"gilead" Discussed on Motley Fool Money

Motley Fool Money

01:41 min | 3 years ago

"gilead" Discussed on Motley Fool Money

"I was her circus gilead sciences uh uh in christine hard juicers a one of the host of our industry focus parked us made this point um you talked about how the been conserving cash christine made the point that the kind of been a pretty steady and growing drumbeat from analysts assorted saying them like when he you can a by someone when he is going to buy another company evidently it reminded me in the conference calls the past many quarters of apple for years i came where's your watchwords your wearable and every quarter tim cooke because like we're working out and they did a good job i think a gilliat as well looks like they made a smart acquisition a deep pipeline for not an outrageous price but chris still what's going to drive the stock the next three years it's going to be the hepatitis market and the hiv market that still where killiadts hat is hanging last year wells fargo was discovered to have created two million fake checking accounts for customers upon further review by an outside auditor wells fargo raised that number two three and a half million fake accounts and matt wall street was completely unfazed by this it's stock didn't drop it'll i know it's disappointing and i think josh brown who is a popular financial blogger he's on seem he sees as money managers great analyst and i think he put it this on twitter yesterday he said if wells fargo was a community bank or any other small business they be driven out and their executives jailed i absolutely believe that but because it's wells fargo because it's a major bank major financial center and because of the number of accounts if you think about in the fees that were were taken in our so tiny realtor the bank's total accounts and in the bank's overall revenue.

gilead sciences apple chris josh brown analyst twitter christine tim cooke wells fargo auditor three years
"gilead" Discussed on Capital Ideas Investing Podcast

Capital Ideas Investing Podcast

02:00 min | 4 years ago

"gilead" Discussed on Capital Ideas Investing Podcast

"And that helped us make gives some real reasons besides the ones usually read about why these companies should be part of our portfolio maybe a top ten position our portfolio look which gears and talk about healthcare you started talking about a little bit meaningful holdings in the fun in in growth fun and elsewhere how we approaching that area but in the area as companies their proceeds is fine and winners and gummy just fine so you can buy a umana because you think in almost every scenario medicare advantage his can i get bigger and better or a bigger that's gonna be funded and grow and i think the number of participants in medicare advantages 'cause it's wrote industry does the stocks you combine this i don't think there's actually a lot of risk to it where you have a lot of risk is in the companies like expressed reps the whole purpose of expressed grips to negotiate price and a par to clients and then yet reaping get paid for rebates it's nasty hail to put it in that put admira it's messy but if the government negotiates price for drugs and you're gonna have a lunch bunch of voters when they when they don't reimburse i certain drug you're gonna have voters subset and express scripts does it and they negotiate for the government that's an area where we're doing a lot of work and but that's wary it's a little more risky because i think the business model is under siege is under discussion but the value is obvious if the business model survives the is going to be a lot of money made and that's part healthcare you have to look at the companies where you're very sure united healthcare new valuations those stocks are y'all fifteen to eighteen times earnings so it's kinda at newmarket kind of recognizes that or you have expressed script salient ninetimes earnings and that's you have to make decision what how much of that too high want then you have these specialty bio at companies with these tremendously wonderful drugs but the pricing is also tremendous and wonderful to feel and that's an area where i think you have to look at the gilead experienced this say.

gilead